CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical translation. We describe a new PRIT approach for the treatment of multiple myeloma (MM) and other B-cell malignancies, for which w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Green, Damian J., O’Steen, Shyril, Lin, Yukang, Comstock, Melissa L., Kenoyer, Aimee L., Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Nartea, Margaret, Hylarides, Mark D., Gopal, Ajay K., Gooley, Theodore A., Orozco, Johnnie J., Till, Brian G., Orcutt, Kelly D., Wittrup, K. Dane, Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805491/
https://ncbi.nlm.nih.gov/pubmed/29158362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-807610
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados